Total Payments
$26,171
2022 Payments
$31.00
Companies
3
Transactions
32
Payment Breakdown by Category
Research$17,694 (67.6%)
Travel$6,446 (24.6%)
Food & Beverage$2,011 (7.7%)
Gifts$20.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17,694 | 6 | 67.6% |
| Travel and Lodging | $6,446 | 17 | 24.6% |
| Food and Beverage | $2,011 | 8 | 7.7% |
| Gift | $20.00 | 1 | 0.1% |
Payments by Type
Research
$17,694
6 transactions
General
$8,477
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $18,769 | 11 | $0 (2022) |
| Novo Nordisk AS | $5,530 | 16 | $0 (2019) |
| PFIZER INC. | $1,873 | 5 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $31.00 | 1 | Eli Lilly and Company ($31.00) |
| 2021 | $34.47 | 2 | PFIZER INC. ($20.00) |
| 2020 | $5,500 | 1 | Eli Lilly and Company ($5,500) |
| 2019 | $11,558 | 12 | Eli Lilly and Company ($8,253) |
| 2018 | $7,319 | 12 | Eli Lilly and Company ($4,970) |
| 2017 | $1,729 | 4 | Novo Nordisk AS ($1,729) |
All Payment Transactions
32 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/15/2022 | Eli Lilly and Company | — | — | In-kind items and services | $31.00 | Research |
| Study: THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | ||||||
| 06/03/2021 | PFIZER INC. | — | Gift | In-kind items and services | $20.00 | General |
| 05/18/2021 | Eli Lilly and Company | — | — | In-kind items and services | $14.47 | Research |
| Study: THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | ||||||
| 04/06/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $5,500.00 | Research |
| Study: THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | ||||||
| 06/05/2019 | Novo Nordisk AS | Ozempic (Drug) | Travel and Lodging | In-kind items and services | $564.04 | General |
| Category: Diabetes | ||||||
| 06/05/2019 | Novo Nordisk AS | Ozempic (Drug) | Travel and Lodging | In-kind items and services | $357.60 | General |
| Category: Diabetes | ||||||
| 06/05/2019 | Novo Nordisk AS | Ozempic (Drug) | Food and Beverage | In-kind items and services | $261.66 | General |
| Category: Diabetes | ||||||
| 06/05/2019 | Novo Nordisk AS | Ozempic (Drug) | Travel and Lodging | In-kind items and services | $229.50 | General |
| Category: Diabetes | ||||||
| 06/05/2019 | Novo Nordisk AS | Ozempic (Drug) | Travel and Lodging | In-kind items and services | $22.50 | General |
| Category: Diabetes | ||||||
| 06/05/2019 | Novo Nordisk AS | Ozempic (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: Diabetes | ||||||
| 03/22/2019 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $809.29 | General |
| 03/22/2019 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $449.74 | General |
| 03/22/2019 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $329.92 | General |
| 03/22/2019 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $264.05 | General |
| 03/06/2019 | Eli Lilly and Company | TRULICITY (Drug) | — | In-kind items and services | $670.28 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS • Category: Diabetes | ||||||
| 01/08/2019 | Eli Lilly and Company | TRULICITY (Drug) | — | Cash or cash equivalent | $7,583.16 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS • Category: Diabetes | ||||||
| 04/11/2018 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $1,140.60 | General |
| 04/11/2018 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $615.18 | General |
| 04/11/2018 | Novo Nordisk AS | — | Food and Beverage | In-kind items and services | $500.30 | General |
| 04/11/2018 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $57.80 | General |
| 04/11/2018 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $30.00 | General |
| 04/11/2018 | Novo Nordisk AS | — | Food and Beverage | In-kind items and services | $4.99 | General |
| 03/26/2018 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $14.36 | General |
| 03/20/2018 | Eli Lilly and Company | TRULICITY (Drug) | — | In-kind items and services | $3,895.19 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS • Category: Diabetes | ||||||
| 03/09/2018 | Eli Lilly and Company | TRULICITY (Drug) | Food and Beverage | In-kind items and services | $325.91 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $12,149 | 3 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $5,545 | 3 |
About Dr. Steven Kaster, MD
Dr. Steven Kaster, MD is a Family Medicine healthcare provider based in Wenatchee, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467478792.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Kaster, MD has received a total of $26,171 in payments from pharmaceutical and medical device companies, with $31.00 received in 2022. These payments were reported across 32 transactions from 3 companies. The most common payment nature is "" ($17,694).
Ad
Practice Information
- Specialty Family Medicine
- Location Wenatchee, WA
- Active Since 07/13/2006
- Last Updated 08/07/2013
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1467478792
Products in Payments
- TRULICITY (Drug) $13,209
- Ozempic (Drug) $1,451
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Wenatchee
Anton Grasch, Md, MD
Family Medicine — Payments: $52,461
Family Medicine $52,461
Andrew Toth, Md, MD
Family Medicine — Payments: $27,689
Family Medicine $27,689
Dr. Alexandre Flor-Henry, Do, DO
Family Medicine — Payments: $1,910
Family Medicine $1,910
Tyler Sherman, D.o, D.O
Family Medicine — Payments: $1,627
Family Medicine $1,627
Cristina Hurlbut, Md, MD
Family Medicine — Payments: $741.31
Family Medicine $741.31
Sunny Bhaskaran, Md, MD
Family Medicine — Payments: $729.38
Family Medicine $729.38